Cefiderocol for treating severe drug-resistant gram-negative bacterial infections

Draft guidance (PDF version) (PDF 274 KB)

Committee meeting

Minutes (MSWord 31 KB)

Agenda : committee slides (PowerPoint 1024 KB)

Agenda : Shionogi evidence submission (MSWord 2.78 MB)

Agenda : Shionogi submission - Data relating to susceptibility studies (MSWord 226 KB)

Agenda : Shionogi submission - MBL susceptibility studies (MSWord 26 KB)

Agenda : Shionogi submission - Merrick cost data (MSWord 18 KB)

Agenda : Patient group submission - Anthony Nolan (MSWord 67 KB)

Agenda : Patient group submission - Antibiotic Research UK (MSWord 75 KB)

Agenda : Professional group submission - British Infection Association (MSWord 60 KB)

Agenda : Professional group submission - Intensive Care Society (MSWord 73 KB)

Agenda : Professional group submission - UK Clinical Pharmacy Association (MSWord 62 KB)

Agenda : Professional group submission - UK Cystic Fibrosis Medical Association (MSWord 63 KB)

Agenda : Anneka Chavda – clinical expert, nominated by the UK Clinical Pharmacy Association (MSWord 63 KB)

Agenda : Alicia Demirjian – clinical expert, nominated by the UK Health Security Agency, formerly known as Public Health England (MSWord 62 KB)

Agenda : Anna Goodman – clinical expert, nominated by the British Infection Association (MSWord 70 KB)

Agenda : Nicola Andrews – patient expert, nominated by Anthony Nolan (MSWord 63 KB)

Agenda : NHS commissioning expert, nominated by NHS England-NHS Improvement (MSWord 59 KB)

Agenda : Assessment report prepared by EEPRU (MSWord 1.94 MB)

Agenda : Assessment report appendices prepared by EEPRU (MSWord 3.58 MB)

Agenda : Comments on the assessment report from Shionogi (MSWord 265 KB)

Agenda : Comments on the assessment report from Shionogi – additional response to economic model (MSWord 79 KB)

Agenda : Comments on the assessment report from British Infection Association (MSWord 37 KB)

Agenda : Comments on the assessment report from British Society for Antimicrobial Chemotherapy-Royal College of Pathologists (MSWord 37 KB)

Agenda : Comments on the assessment report from NHS England-NHS Improvement (MSWord 35 KB)

Agenda : Comments on the assessment report from Merck Sharpe & Dohme (MSWord 37 KB)

Agenda : Comments on the assessment report from Pfizer (MSWord 838 KB)

Agenda : Comments on the assessment report from Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection (MSWord 36 KB)

Agenda : EEPRU’s response to consultee and commentator comments on their assessment report (MSWord 33 KB)

Agenda : Additional analyses - addendum 1 (MSWord 334 KB)

Agenda : Additional analyses - addendum 2 (MSWord 679 KB)

Agenda : Pre-meeting briefing (PowerPoint 3.48 MB)

Agenda : Key issues for committee discussion (MSWord 55 KB)

Draft scope (pdf version) (PDF 192 KB)

Supporting documentation : Draft stakeholder list (PDF 142 KB)

Supporting documentation : Equality impact assessment (MSWord 19 KB)

Final protocol (MSWord 385 KB)

Final protocol Addendum: updated PICO tables (MSWord 23 KB)

Final scope (MSWord 37 KB)

Stakeholder list : Final (MSWord 27 KB)

NICE’s response to comments on draft scope (MSWord 119 KB)